Back to Careers Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1. MDA_DM1JUV161_portrait_poster_FINAL_compressedDownload